Institutional members access full text with Ovid®

Share this article on:

Grapes, Wines, Resveratrol, and Heart Health

Bertelli, Alberto A A MD, PhD*; Das, Dipak K PhD, ScD, FAHA

Journal of Cardiovascular Pharmacology: December 2009 - Volume 54 - Issue 6 - p 468-476
doi: 10.1097/FJC.0b013e3181bfaff3
Invited Review Article

Epidemiological and experimental studies have revealed that a mild to moderate drinking of wine, particularly red wine, attenuates the cardiovascular, cerebrovascular, and peripheral vascular risk. However, the experimental basis for such health benefits is not fully understood. The cardioprotective effect of wine has been attributed to both components of wine: the alcoholic portion and, more importantly, the alcohol-free portion containing antioxidants. Wines are manufactured from grapes, which also contain a large variety of antioxidants, including resveratrol, catechin, epicatechin, and proanthocyanidins. Resveratrol is mainly found in the grape skin, whereas proanthocyanidins are found only in the seeds. Recent studies have demonstrated that resveratrol and proanthocyanidin are the major compounds present in grapes and wines responsible for cardioprotection. The purpose of this review is to provide evidence that grapes, wines, and resveratrol are equally important in reducing the risk of morbidity and mortality due to cardiovascular complications. Both wines and grapes can attenuate cardiac diseases such as atherosclerosis and ischemic heart disease. Recently, wine was also found to increase life span by inducing longevity genes. It appears that resveratrol and proanthocyanidins, especially resveratrol, present in grapes and wines play a crucial role in cardioprotective abilities of grapes and wines.

From the *Institute of Human Anatomy, University of Milan, Milan, Italy; and †Cardiovascular Research Center, University of Connecticut School of Medicine, Farmington, CT.

Received for publication April 23, 2009; accepted August 21, 2009.

Supported in part by National Institutes of Health HL 22559, HL 3388, and HL 56803.

The authors report no conflicts of interest.

Reprints: Dipak K. Das, PhD, ScD, FAHA, Cardiovascular Research Center, University of Connecticut School of Medicine, Farmington, CT 06030-1110 (e-mail: DDAS@NEURON.UCHC.EDU).

© 2009 Lippincott Williams & Wilkins, Inc.